Clinical Trials Logo

p16 Protein clinical trials

View clinical trials related to p16 Protein.

Filter by:
  • None
  • Page 1

NCT ID: NCT06439433 Completed - Clinical trials for Papillomavirus Infections

ALA-PDT in Patients With CIN2 in p16-positivity and High-risk HPV Infection

Start date: May 31, 2021
Phase: Phase 2
Study type: Interventional

Efficacy and Safety of ALA-PDT in patients with cervical intraepithelial neoplasia grade 2 (CIN2) in p16-positivity and high-risk HPV infection.

NCT ID: NCT04650711 Recruiting - Clinical trials for Cervical Intraepithelial Neoplasia

Immunohistochemical Staining of p16 for the Screening of Cervical Cancer

Start date: November 26, 2020
Phase: Phase 2
Study type: Interventional

Cyclin kinase inhibitor P16INK4A has overexpression in cervical cancer, and hence becoming an alternative method for cervical cancer screening. This study is to investigate the clinical value of P16INK4A and high-risk human papillomavirus (hrHPV) detection of cervical intraepithelial neoplasia (CIN) 2 or more severe lesions (CIN2+). All eligible participants accept P16INK4A testing, with cytology and/or hrHPV assay. P16INK4A immunohistochemical staining is performed on the retained specimens of cytology. The primary endpoint is the diagnostic accuracy of P16INK4A compared with cytology and/or hrHPV status based on histology results. The accuracy analysis includes sensitivity, specificity, negative predictive value and positive predictive value.